These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34121166)

  • 1. Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.
    Tatekawa H; Uetani H; Hagiwara A; Bahri S; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    Ann Nucl Med; 2021 Sep; 35(9):1022-1029. PubMed ID: 34121166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study.
    Tatekawa H; Yao J; Oughourlian TC; Hagiwara A; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Salamon N; Ellingson BM
    Clin Nucl Med; 2020 Dec; 45(12):e505-e511. PubMed ID: 33031233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
    Tatekawa H; Hagiwara A; Uetani H; Yao J; Oughourlian TC; Bahri S; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    J Neurooncol; 2020 Sep; 149(2):337-346. PubMed ID: 32929644
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
    J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutation is paradoxically associated with higher
    Verger A; Metellus P; Sala Q; Colin C; Bialecki E; Taieb D; Chinot O; Figarella-Branger D; Guedj E
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1306-1311. PubMed ID: 28293705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of change in maximum
    Oughourlian TC; Yao J; Schlossman J; Raymond C; Ji M; Tatekawa H; Salamon N; Pope WB; Czernin J; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
    J Neurooncol; 2020 Mar; 147(1):135-145. PubMed ID: 31981013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high
    Isal S; Gauchotte G; Rech F; Blonski M; Planel S; Chawki MB; Karcher G; Marie PY; Taillandier L; Verger A
    Br J Radiol; 2018 Apr; 91(1084):20170803. PubMed ID: 29271237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voxelwise and Patientwise Correlation of
    Tatekawa H; Hagiwara A; Yao J; Oughourlian TC; Ueda I; Uetani H; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    J Nucl Med; 2021 Mar; 62(3):319-325. PubMed ID: 32646876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET.
    Tatekawa H; Hagiwara A; Uetani H; Bahri S; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    Cancer Imaging; 2021 Mar; 21(1):27. PubMed ID: 33691798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.
    Wang Y; Fushimi Y; Arakawa Y; Shimizu Y; Sano K; Sakata A; Nakajima S; Okuchi S; Hinoda T; Oshima S; Otani S; Ishimori T; Tanji M; Mineharu Y; Yoshida K; Nakamoto Y
    Jpn J Radiol; 2023 Nov; 41(11):1255-1264. PubMed ID: 37219717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential tumor localization in relation to
    Tatekawa H; Uetani H; Hagiwara A; Yao J; Oughourlian TC; Ueda I; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Bahri S; Pope WB; Salamon N; Ellingson BM
    J Neurooncol; 2021 May; 152(3):573-582. PubMed ID: 33704629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the mechanism of 18F-fluorodopa uptake in recurrent high-grade gliomas: A comprehensive histomolecular-positron emission tomography analysis.
    Cobes N; Tran S; Mathon B; Nichelli L; Bielle F; Touat M; Kas A; Rozenblum L
    Eur J Neurol; 2024 Jan; 31(1):e16093. PubMed ID: 37823694
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
    Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
    AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
    Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
    Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
    Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.